BioInformant - Stem Cell Industry News
@bioinformant.bsky.social
As the first and only market research firm to specialize in the stem cell industry, BioInformant.com is read by nearly 1 million readers per year. BioInformant has been cited by WSJ, Xconomy, and Vogue, as well as featured in Tony Robbin's book Life Force.
AABB To Run Limited-Time Certified Advanced Biotherapies Professional (CABP) Free Exam Retake Offer - bioinformant.com/aabb-certifi...
@aabbupdates.bsky.social
@aabbupdates.bsky.social
AABB To Run Limited-Time Certified Advanced Biotherapies Professional (CABP) Free Exam Retake Offer | BioInformant
December 2, 2025, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce a limited-time Certified Advanced Biotherapies Professional (CABP) free exam ...
bioinformant.com
December 3, 2025 at 10:43 AM
AABB To Run Limited-Time Certified Advanced Biotherapies Professional (CABP) Free Exam Retake Offer - bioinformant.com/aabb-certifi...
@aabbupdates.bsky.social
@aabbupdates.bsky.social
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach
REPROCELL functions as a true one-stop stem cell biotech, unifying the entire #iPSC value chain under a single, dependable partner.
bioinformant.com/gmp-manufact...
@reprocell.bsky.social
REPROCELL functions as a true one-stop stem cell biotech, unifying the entire #iPSC value chain under a single, dependable partner.
bioinformant.com/gmp-manufact...
@reprocell.bsky.social
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach | BioInformant
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing serv...
bioinformant.com
December 2, 2025 at 4:43 PM
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach
REPROCELL functions as a true one-stop stem cell biotech, unifying the entire #iPSC value chain under a single, dependable partner.
bioinformant.com/gmp-manufact...
@reprocell.bsky.social
REPROCELL functions as a true one-stop stem cell biotech, unifying the entire #iPSC value chain under a single, dependable partner.
bioinformant.com/gmp-manufact...
@reprocell.bsky.social
Cell Therapy Industry News Round-Up: November 2, 2025 - bioinformant.com/cell-therapy...
@cirmnews.bsky.social @slingshotbio.bsky.social
@cirmnews.bsky.social @slingshotbio.bsky.social
Cell Therapy Industry News Round-Up: November 2, 2025 | BioInformant
The Cell and Gene Therapy Industry Accelerates with New Financing, Partnerships, and Clinical Milestones The cell and gene therapy (CGT) sector is entering the final quarter of 2025 with remarkable mo...
bioinformant.com
December 1, 2025 at 12:12 PM
Cell Therapy Industry News Round-Up: November 2, 2025 - bioinformant.com/cell-therapy...
@cirmnews.bsky.social @slingshotbio.bsky.social
@cirmnews.bsky.social @slingshotbio.bsky.social
What is CAR-T Cell Therapy? A New Way to Treat Cancer - bioinformant.com/car-t-cell-t...
@novartis.bsky.social @bristolmyerssquibb.bsky.social
@novartis.bsky.social @bristolmyerssquibb.bsky.social
What is CAR-T Cell Therapy? A New Way to Treat Cancer | Bioinformant
How does CAR-T cell therapy work? CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize & destroy cancer.
bioinformant.com
November 26, 2025 at 2:10 AM
What is CAR-T Cell Therapy? A New Way to Treat Cancer - bioinformant.com/car-t-cell-t...
@novartis.bsky.social @bristolmyerssquibb.bsky.social
@novartis.bsky.social @bristolmyerssquibb.bsky.social
Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access - bioinformant.com/vector-biome...
Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access | BioInformant
The expansion of LENTIVERSE™ platform introduces “One Lentiviral Vector Platform, Two Paths to Advance Cures,” aligning scientific rigor with transparent economics and global accessibility. GAITHERSBU...
bioinformant.com
November 22, 2025 at 2:26 AM
Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access - bioinformant.com/vector-biome...
Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB - bioinformant.com/ipsc-derived...
Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB | BioInformant
Allogeneic iPSC-derived therapies hold immense promise, offering scalable, off-the-shelf solutions for a wide spectrum of diseases. However, the journey from donor cells to a gene edited, clinically c...
bioinformant.com
November 20, 2025 at 7:42 AM
Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB - bioinformant.com/ipsc-derived...
Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology - bioinformant.com/applied-stem...
@appliedstemcell.bsky.social
@appliedstemcell.bsky.social
Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology | BioInformant
MILPITAS, Calif., Nov. 11, 2025 – Applied StemCell, Inc. (ASC), today announced the successful knock-in of a 50 kilobase (kb) multifunctional DNA insert into human induced pluripotent stem cells (iPSC...
bioinformant.com
November 19, 2025 at 10:33 AM
Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology - bioinformant.com/applied-stem...
@appliedstemcell.bsky.social
@appliedstemcell.bsky.social
🔬GMP-ready iPSC line development starts on day one. Many teams use R&D workflows early, then face major gaps at GMP, from non-compliant reagents to missing documentation.
Learn how to avoid these pitfalls in Cellistic's Nov 19 webinar at 11am EST:
Register here: www.cellistic.com/insights/web...
Learn how to avoid these pitfalls in Cellistic's Nov 19 webinar at 11am EST:
Register here: www.cellistic.com/insights/web...
Webinar: Redefining iPSC Genome Editing for Next-Generation Cell Therapies
A deep dive into optimizing genome editing for iPSC therapies through improved design, performance, and regulatory alignment.
www.cellistic.com
November 19, 2025 at 2:32 AM
🔬GMP-ready iPSC line development starts on day one. Many teams use R&D workflows early, then face major gaps at GMP, from non-compliant reagents to missing documentation.
Learn how to avoid these pitfalls in Cellistic's Nov 19 webinar at 11am EST:
Register here: www.cellistic.com/insights/web...
Learn how to avoid these pitfalls in Cellistic's Nov 19 webinar at 11am EST:
Register here: www.cellistic.com/insights/web...
Global Database of Cultured (“Clean”) Meat Companies, 2025 - bioinformant.com/product/cult...
Global Database of Cultured Meat Companies, 2025
This global database of cultured meat companies features all known companies worldwide who are developing lab-grown meat and animal products.
bioinformant.com
November 15, 2025 at 7:58 PM
Global Database of Cultured (“Clean”) Meat Companies, 2025 - bioinformant.com/product/cult...
iOrganBio Emerges from Stealth with $2M and Launches CellForge™, the First AI-Powered Cell Manufacturing Platform - bioinformant.com/iorganbio-em...
iOrganBio Emerges from Stealth with $2M and Launches CellForge™, the First AI-Powered Cell Manufacturing Platform | BioInformant
Founded by deep scientific experts across biomedical engineering, stem cell biology and organoid systems Funding round led by First Star Ventures October 29, 2025, CHAPEL HILL, NC — iOrganBio announce...
bioinformant.com
November 13, 2025 at 7:45 PM
iOrganBio Emerges from Stealth with $2M and Launches CellForge™, the First AI-Powered Cell Manufacturing Platform - bioinformant.com/iorganbio-em...
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - bioinformant.com/ipsc-derived...
@aspenneuroscience.bsky.social @greenstonebio.bsky.social @novonordisk.bsky.social @reprocell.bsky.social @riken-brc-en.bsky.social
@aspenneuroscience.bsky.social @greenstonebio.bsky.social @novonordisk.bsky.social @reprocell.bsky.social @riken-brc-en.bsky.social
The Pipeline for of iPSC-Derived Cell Therapeutics in 2026
While iPSCs are commonly used in drug discovery, we remain in the early stages of using iPSC-derived cell therapeutics in humans.
bioinformant.com
November 10, 2025 at 4:39 PM
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - bioinformant.com/ipsc-derived...
@aspenneuroscience.bsky.social @greenstonebio.bsky.social @novonordisk.bsky.social @reprocell.bsky.social @riken-brc-en.bsky.social
@aspenneuroscience.bsky.social @greenstonebio.bsky.social @novonordisk.bsky.social @reprocell.bsky.social @riken-brc-en.bsky.social
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based - An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD | BioInformant
In the rapidly evolving field of cell therapy, scalability and accessibility remain two of the biggest challenges for widespread patient impact. Cellistic, a leading company that is pioneering allogen...
bioinformant.com
November 9, 2025 at 5:46 AM
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 - bioinformant.com/roosterbio-a...
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 | BioInformant
FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Se...
bioinformant.com
November 6, 2025 at 3:48 PM
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 - bioinformant.com/roosterbio-a...
BBG Advanced Therapies collects first cell donation on one-of-a-kind bus - bioinformant.com/bbg-advanced...
The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.
The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.
BBG Advanced Therapies collects first cell donation on one-of-a-kind bus | BioInformant
New vehicle to help enable lifesaving new advanced therapies The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global ...
bioinformant.com
October 29, 2025 at 7:14 PM
BBG Advanced Therapies collects first cell donation on one-of-a-kind bus - bioinformant.com/bbg-advanced...
The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.
The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - bioinformant.com/big-pharma-c...
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering | BioInformant
Across 2025, a striking trend has emerged in biotechnology. Major pharmaceutical companies are racing to acquire in vivo cell engineering platforms, signaling that reprogramming cells inside the body ...
bioinformant.com
October 27, 2025 at 2:56 AM
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - bioinformant.com/big-pharma-c...
CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research - bioinformant.com/cirms-ipsc-r...
@cirmnews.bsky.social
@cirmnews.bsky.social
CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research | BioInformant
Sadly, in July 2025, the California Institute for Regenerative Medicine (CIRM) officially closed its iPSC Repository, marking the end of one of the world’s most comprehensive publicly funded collectio...
bioinformant.com
October 24, 2025 at 6:56 AM
CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research - bioinformant.com/cirms-ipsc-r...
@cirmnews.bsky.social
@cirmnews.bsky.social
NFL legend Bernie Kosar launches the X Pro Athlete Cognitive Longevity Program with the Crowley Center and Regenerelle® to push the limits of brain performance
bioinformant.com/bernie-kosar...
bioinformant.com/bernie-kosar...
Legendary NFL Quarterback Bernie Kosar Launches X Pro. Athlete Cognitive Longevity Wellness Program to Push the Limits of Brain Performance with Crowley Center for Regenerative Biotherapeutics in coll...
Backed by a $10M Age Zero™ Regenerelle® in-kind contribution by the Crowley Family, Team Bernie™ brings together NFL veterans and longevity innovators to explore next-generation cognitive optimizatio...
bioinformant.com
October 23, 2025 at 8:22 PM
NFL legend Bernie Kosar launches the X Pro Athlete Cognitive Longevity Program with the Crowley Center and Regenerelle® to push the limits of brain performance
bioinformant.com/bernie-kosar...
bioinformant.com/bernie-kosar...
Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease - bioinformant.com/qihan-biotec...
Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease | BioInformant
A new chapter is beginning for iPSCs: Qihan Biotech, a leading innovator in cell engineering, has reported the first clinical use of an induced pluripotent stem cell (iPSC)-derived CAR natural killer ...
bioinformant.com
October 19, 2025 at 2:44 AM
Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease - bioinformant.com/qihan-biotec...
Induced Pluripotent Stem Cell (iPSC) Industry Trends Dominating in 2025 - bioinformant.com/ipsc-industr...
@riken-brc-jp.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social
@riken-brc-jp.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social
Induced Pluripotent Stem Cell (iPSC) Industry Trends for 2025
Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using non-controversial adult cells. They are derived from somatic cells through reprog...
bioinformant.com
October 18, 2025 at 1:02 PM
Induced Pluripotent Stem Cell (iPSC) Industry Trends Dominating in 2025 - bioinformant.com/ipsc-industr...
@riken-brc-jp.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social
@riken-brc-jp.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social
Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential - bioinformant.com/novo-withdra...
@novonordisk.bsky.social
@novonordisk.bsky.social
Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential | BioInformant
Sadly, Novo Nordisk has ended its $598 million collaboration with Tokyo-based biotech Heartseed, marking a major shift in its approach to regenerative medicine and iPSCs, specifically. The partnershi...
bioinformant.com
October 14, 2025 at 8:00 PM
Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential - bioinformant.com/novo-withdra...
@novonordisk.bsky.social
@novonordisk.bsky.social
TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee - bioinformant.com/trihaz-solut...
TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee | BioInformant
Nashville, TN – July 16, 2025 – TriHaz Solutions, a trusted provider of regulated medical waste management, is proud to announce the opening of a new operational facility in Nashville, Tennesee. This ...
bioinformant.com
October 12, 2025 at 5:30 PM
TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee - bioinformant.com/trihaz-solut...
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells - bioinformant.com/ubrigene-ips...
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells | BioInformant
GERMANTOWN, MD, September 17, 2025 – uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, announced the launch of its 2nd-Generation iPSC Reprogramming Kit, powere...
bioinformant.com
October 10, 2025 at 6:57 AM
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells - bioinformant.com/ubrigene-ips...
TEDCO Announces Panel to Discuss Road to Clinical Trials at 2025 Entrepreneur Expo - bioinformant.com/tedco-panel-...
TEDCO, MD's economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo.
TEDCO, MD's economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo.
TEDCO Announces Panel to Discuss the Road to Clinical Trials at 2025 Entrepreneur Expo | BioInformant
COLUMBIA, Md., October 9, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo at ...
bioinformant.com
October 10, 2025 at 12:38 AM
TEDCO Announces Panel to Discuss Road to Clinical Trials at 2025 Entrepreneur Expo - bioinformant.com/tedco-panel-...
TEDCO, MD's economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo.
TEDCO, MD's economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo.
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study - bioinformant.com/xintelas-xst...
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study | BioInformant
The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pa...
bioinformant.com
October 9, 2025 at 6:01 PM
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study - bioinformant.com/xintelas-xst...
Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF - bioinformant.com/kexing-bioph...
Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF | BioInformant
SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (...
bioinformant.com
October 9, 2025 at 1:18 AM
Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF - bioinformant.com/kexing-bioph...